Going Concern (Details Textual) - USD ($) |
1 Months Ended | 3 Months Ended | 6 Months Ended | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jan. 07, 2019 |
Feb. 28, 2019 |
Jan. 31, 2019 |
Jan. 30, 2019 |
Dec. 31, 2018 |
Dec. 31, 2017 |
Sep. 30, 2017 |
Dec. 31, 2020 |
Dec. 31, 2018 |
Dec. 31, 2017 |
Sep. 30, 2018 |
Jun. 30, 2018 |
Jun. 30, 2017 |
|
| Going Concern [Line Items] | |||||||||||||
| Net Loss | $ (4,161,432) | $ (5,718,587) | $ (6,684,612) | $ (7,526,665) | $ (12,403,200) | ||||||||
| Net Cash Used In Operating Activities | (3,082,823) | (8,052,651) | |||||||||||
| Total Stockholders' Equity | (9,787,694) | $ 3,801,798 | $ 7,805,901 | (9,787,694) | $ 3,801,798 | $ (6,443,181) | $ (3,960,755) | $ 8,527,967 | |||||
| Accumulated deficit | (101,710,403) | (101,710,403) | $ (94,183,738) | ||||||||||
| Working Capital Deficit | $ 2,600,000 | $ 2,600,000 | |||||||||||
| Preferred Stock, Shares Issued | 0 | 0 | 0 | ||||||||||
| Common Stock Shares Authorized Value | $ 20,000,000 | ||||||||||||
| Description of Share Price Decision upon Conditions Given | at a per share price equal to the greater of $0.29 or 75% of the volume weighted average closing price of the Company’s common stock over 30 consecutive trading days prior to the exercise of the option | ||||||||||||
| Common Stock, Call or Exercise Features | The Company currently expects to request additional funding from the New Investors during the second half of calendar 2019. However, there are no assurances that the New Investors will elect to exercise their rights to invest up to an additional $20.0 million | ||||||||||||
| Exclusivity Payment | $ 1,500,000 | $ 1,500,000 | $ 0 | ||||||||||
| License [Member] | |||||||||||||
| Going Concern [Line Items] | |||||||||||||
| Legal Fees | $ 5,900,000 | ||||||||||||
| Clinical Program [Member] | |||||||||||||
| Going Concern [Line Items] | |||||||||||||
| Net Proceeds Available from the Proceeds of Issuance of Preferred Stock | $ 17,600,000 | ||||||||||||
| Convertible Preferred Stock [Member] | |||||||||||||
| Going Concern [Line Items] | |||||||||||||
| Preferred Stock, Shares Outstanding | 113,600,000 | ||||||||||||
| Debt Instrument, Face Amount | 5,340,000 | $ 5,340,000 | |||||||||||
| Component on Preferred stock Accrued Shares | 771,000 | ||||||||||||
| Preference Shares Converted into Common Stock Shares | 35,000,000 | ||||||||||||
| Increase in number of Preference shares to Common Stock Authorized Minimum | 500,000,000 | ||||||||||||
| Series AA Preferred Stock [Member] | |||||||||||||
| Going Concern [Line Items] | |||||||||||||
| Preferred Stock, Shares Issued | 2,500,000 | ||||||||||||
| Proceeds from Issuance of Preferred Stock and Preference Stock | $ 25,000,000 | $ 25,000,000 | $ 25,000,000 | ||||||||||
| Remaining Proceeds from Issuance of Preferred Stock | $ 23,500,000 | ||||||||||||
| Preferred Stock, Shares Outstanding | 2,500,000 | ||||||||||||